Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.62 |
| ▸ | HTR3B | O95264 | 1/20 | 0.62 |
| ▸ | HTR5A | P47898 | 1/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | HTR6 | P50406 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144739 | 0.93 | HTR3A (0.87) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL12806786 | 0.84 | HTR3A (0.72) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL29594813 | 0.82 | HTR3A (0.69) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL3534699 | 0.82 | HTR3A (0.69) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL4649484 | 0.81 | HTR3A (0.69) | HTR3ANPC1RAB9AHTR7ADRA2C | |
| SCHEMBL20784267 | 0.81 | HTR3A (0.69) | HTR3ANPC1RAB9AADRA2CRAD52 | |
| SCHEMBL18741375 | 0.80 | HTR3A (0.67) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL4810527 | 0.80 | HTR3A (0.67) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL30480097 | 0.80 | HTR3A (0.67) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL22728551 | 0.80 | HTR3A (0.66) | HTR3ASIGMAR1HTR3EHTR3BHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4169919-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-105669597-B | Amyloid bonding agent | 加利福尼亚大学董事会 | 2019-05-07 | — | — | CN | disclosed |
| CN-109422754-A | Pyrazolo [3,4-d] pyrimidine -3- ketone derivatives, its pharmaceutical composition and application | 上海迪诺医药科技有限公司 | 2019-03-05 | — | — | CN | disclosed |
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1603395-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080170-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | CBR3, L3MBTL3, BRS3 | HTR3A 663/4885SIGMAR1 1480/4885HTR3E 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.